Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia
United States Nuclear Regulatory Commission · Baylor College of Medicine · +1 more institution
Abstract
BACKGROUND: Despite the established efficacy of statins, many patients do not achieve recommended LDL cholesterol (LDL-C) goals. Contributing factors may be inadequate dosing, increased risk for adverse effects with high-dose monotherapy, and increased potential for intolerance and adverse effects with combinations of available agents. METHODS AND RESULTS: In a double-blind study, 628 patients with baseline LDL-C 145 to 250 mg/dL and triglycerides
Citation impact
- FWCI
- 65.82
- Percentile
- 100%
- References
- 22
Authors
10- CMChristie M. BallantyneCorresponding
United States Nuclear Regulatory Commission, Baylor College of Medicine, Radiant Research (United States)
- JHJohn Houri
United States Nuclear Regulatory Commission, Baylor College of Medicine, Radiant Research (United States)
- ANA Notarbartoló
United States Nuclear Regulatory Commission, Baylor College of Medicine, Radiant Research (United States)
- LMLorenzo Melani
United States Nuclear Regulatory Commission, Baylor College of Medicine, Radiant Research (United States)
- LLLeslie Lipka
United States Nuclear Regulatory Commission, Baylor College of Medicine, Radiant Research (United States)
Topics & keywords
- Ezetimibe
- Atorvastatin
- Medicine
- Triglyceride
- Placebo
- Pharmacology
- Internal medicine
- Cholesterol
- Good health and well-being